Lobenzarit sodium

• CAT Number: I030944
• CAS Number: 64808-48-6
• Molecular Formula: C14H8ClNNa2O4
• Molecular Weight: 335.65
• Purity: 98%
• Synonyms: Lobenzarit sodium; CCA
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: sodium 2-((2-carboxylatophenyl)amino)-4-chlorobenzoate
• InChI: InChI=1S/C14H10ClNO4.2Na/c15-8-5-6-10(14(19)20)12(7-8)16-11-4-2-1-3-9(11)13(17)18;;/h1-7,16H,(H,17,18)(H,19,20);;/q;2*+1/p-2
• InChIKey: QPJBONAWFAURGB-UHFFFAOYSA-L
• SMILES: O=C([O-])C1=CC=C(Cl)C=C1NC2=CC=CC=C2C([O-])=O.[Na+].[Na+]

Lobenzarit sodium (CAST: I030944) is an antirheumatic agent that holds promise in the management of rheumatoid arthritis and related inflammatory conditions. By exerting its effects on the immune system and inflammatory processes, lobenzarit sodium aims to alleviate the symptoms associated with these conditions. Its mechanism of action likely involves the modulation of immune responses and cytokine production, which are central to the pathogenesis of rheumatoid arthritis. Lobenzarit sodium’s potential to dampen the inflammatory cascade and mitigate joint damage makes it a candidate for therapeutic interventions aimed at improving the quality of life for individuals affected by rheumatic diseases.

Reference

1: Remirez D, Commandeur JN, Groot E, Vermeulen NP. Mechanism of protection of lobenzarit against paracetamol-induced toxicity in rat hepatocytes. Eur J Pharmacol. 1995 Dec 7;293(4):301-8. PubMed PMID: 8748682.
2: Sakane N, Yoshida T, Umekawa T, Miyazaki R, Kondo M. Nephrogenic diabetes insipidus induced by lobenzarit disodium treatment in patients with rheumatoid arthritis. Intern Med. 1996 Feb;35(2):119-22. Review. PubMed PMID: 8680099.
3: Evans GL, Gamage SA, Bulloch EM, Baker EN, Denny WA, Lott JS. Repurposing the chemical scaffold of the anti-arthritic drug Lobenzarit to target tryptophan biosynthesis in Mycobacterium tuberculosis. Chembiochem. 2014 Apr 14;15(6):852-64. doi: 10.1002/cbic.201300628. Epub 2014 Mar 12. Erratum in: Chembiochem. 2015 Mar 23;16(5):706. Chembiochem. 2015 Mar 23;16(5):706. PubMed PMID: 24623674.
4: Remirez D, Commandeur JN, Groot E, Gonzalez R, Rodriguez S, Ancheta O, Rojas E, Ramos ME, Vermeulen NP. Protective effects of lobenzarit against allyl alcohol-induced hepatotoxicity in mice and rats. Environ Toxicol Pharmacol. 1997 Jun 6;3(2):129-35. PubMed PMID: 21781770.
5: González R, Pascual C, Ancheta O, Carreras B, Remírez D, Pellón R. Hepatoprotective effects of lobenzarit disodium on acetaminophen-induced liver damage in mice. Agents Actions. 1992 Sep;37(1-2):114-20. PubMed PMID: 1456172.
6: Shiokawa Y, Horiuchi Y, Mizushima Y, Kageyama T, Shichikawa K, Ofuji T, Honma M, Yoshizawa H, Abe C, Ogawa N. A multicenter double-blind controlled study of lobenzarit, a novel immunomodulator, in rheumatoid arthritis. J Rheumatol. 1984 Oct;11(5):615-23. PubMed PMID: 6392550.
7: Kishimoto C, Takada H, Kuroki Y, Matsushita I, Hiraoka Y, Kurokawa M, Ochiai H, Sasayama S. Enhancement of coxsackievirus B3 myocarditis in mice by lobenzarit disodium through inhibition of splenic pan T cells. Cardiovasc Res. 1993 Feb;27(2):243-8. PubMed PMID: 8386064.
8: Castellanos Gil E, Iraizoz Colarte A, Bataille B, Brouillet F, Caraballo I. Estimation of the percolation thresholds in ternary lobenzarit disodium-dextran-HPMC hydrophilic matrices tablets: effects of initial porosity. Eur J Pharm Sci. 2009 Nov 5;38(4):312-9. doi: 10.1016/j.ejps.2009.07.013. Epub 2009 Aug 8. PubMed PMID: 19666114.
9: Hirohata S, Ohnishi K, Sagawa A. Treatment of systemic lupus erythematosus with lobenzarit: an open clinical trial. Clin Exp Rheumatol. 1994 May-Jun;12(3):261-5. PubMed PMID: 8070158.
10: Ohuchi K, Watanabe M, Fukui Y, Hirasawa N, Ozeki T, Tsurufuji S. The effect of diphenylamine derivatives on arachidonic acid metabolism in rat peritoneal macrophages. Prostaglandins Leukot Med. 1987 Jun;28(1):15-23. PubMed PMID: 3112805.
11: Andou S, Fujii S, Harada Y, Ooi J, Nomiyama J, Mori K, Ookubo M, Azuno Y, Fujii Y, Kaku K, et al. Alpha-methyldopa-type autoimmune hemolytic anemia caused by lobenzarit disodium of a mefenamic acid derivative and immunomodulator. Blood. 1994 May 15;83(10):3097. PubMed PMID: 8180406.
12: González R, Remírez D. Current views on the pharmacological properties of the immunomodulator, lobenzarit disodium. J Investig Allergol Clin Immunol. 1997 Mar-Apr;7(2):77-82. Review. PubMed PMID: 9161931.
13: Nishinarita S, Hayakawa J, Suzuki R, Hayama T, Hiranuma M, Sawada S, Horie T. [Lobenzarit disodium (CCA)–induced diabetes insipidus in a patient with rheumatoid arthritis]. Ryumachi. 1992 Aug;32(4):333-7; discussion 337-9. Japanese. PubMed PMID: 1411795.
14: Hirohata S, Shinohara S, Inoue T, Miyamoto T, Lipsky PE. Regulation of B cell function by lobenzarit, a novel disease-modifying antirheumatic drug. Arthritis Rheum. 1992 Feb;35(2):168-75. PubMed PMID: 1734906.
15: Evans GL, Gamage SA, Bulloch EM, Baker EN, Denny WA, Lott JS. Corrigendum: Repurposing the Chemical Scaffold of the Anti-Arthritic Drug Lobenzarit to Target Tryptophan Biosynthesis in Mycobacterium tuberculosis. Chembiochem. 2015 Mar 23;16(5):706. doi: 10.1002/cbic.201500098. Epub 2015 Mar 11. PubMed PMID: 26177917.
16: Yamashita Y, Nakano T, Ohsugi Y. New immunomodulator lobenzarit disodium (CCA): activation of IgE class-specific suppressor T lymphocytes and regulation of IgE antibody response enhanced by sublethal X-irradiation in SJL/J mice. Int Arch Allergy Appl Immunol. 1987;83(3):296-302. PubMed PMID: 2954916.
17: Armesto J, Frutos N, Gonzalez R, Pascual C. In vitro activation of hepatic glutathione reductase from mice by lobenzarit disodium. Agents Actions. 1993 May;39(1-2):69-71. PubMed PMID: 8285143.
18: Cynshi O, Saitoh M, Cynshi F, Tanemura M, Hata S, Nakano M. Anti-oxidative profile of lobenzarit disodium (CCA). Biochem Pharmacol. 1990 Nov 1;40(9):2117-22. PubMed PMID: 2242038.
19: Haynes DR, Gadd SJ, Whitehouse MW, Mayrhofer G, Vernon-Roberts B. Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporin-A and lobenzarit: the regulation of lymph node cell populations and cytokine production. Inflamm Res. 1996 Apr;45(4):159-65. PubMed PMID: 8741004.
20: Miranda A, Millán M, Caraballo I. Study of the critical points in lobenzarit disodium hydrophilic matrices for controlled drug delivery. Chem Pharm Bull (Tokyo). 2006 May;54(5):598-602. PubMed PMID: 16651752.